In addition, when combined with EGFR TKI treatment, USP17 depletion could induce apoptosis in EGFRWT NSCLC cells, indicating USP17 inhibition can improve the efficacy and expand the susceptible patient cohort for these drugs. Here, EGFR is linked to non-small cell lung carcinoma.